Open AccessHIV, HCV and SARS-CoV-2: friends or foes? A case report
Author(s) -
Enrico Costa,
Cesare Mazzaro,
Alessandro Grembiale,
Alessandra Berto,
Rita De Rosa,
Santina Grazioli,
Maurizio Tonizzo
Publication year - 2021
Publication title -
italian journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.134
H-Index - 10
eISSN - 1877-9352
pISSN - 1877-9344
DOI - 10.4081/itjm.2021.1350
Subject(s) - medicine , emtricitabine , myalgia , sore throat , virology , didanosine , immunology , lamivudine , virus , chronic hepatitis
Data about co-infection of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), HIV, and hepatitis C virus (HCV) are still scarce. We describe a patient hospitalized for sore throat, fatigue, and myalgia with a personal history of HIV and occult HBV infection. His antiretroviral therapy included bictegravir/emtricitabine/tenofovir alafenamide. The nasopharyngeal swab was positive for SARS-CoV-2 and laboratory testing showed acute HCV. Antiretroviral therapy was continued, but no specific therapy for SARS-CoV-2 was started. After 4 weeks, the nasopharyngeal swab resulted negative for SARS-CoV-2 and biochemical tests revealed undetectable HCV RNA with normalization of transaminases. To the best of our knowledge, this is the first reported case of acute HCV in a patient with HIV and SARS-CoV-2 co-infection.